Oststeinbek, Germany
ROXALL Group is an international pharmaceutical company based in Hamburg, Germany. The company's core business revolves around pharmaceuticals for allergen immunotherapy - a causal allergy therapy recognized by the World Health Organization (WHO). Notably, this therapy not only prevents allergies from progressing into asthma but also inhibits the development of new sensitivities. The company is dedicated to advancing its treatments and manufacturing top-quality products, resulting in numerous groundbreaking innovations within the field.
ROXALL Group maintains subsidiaries in Europe, Asia, and Latin America. The acquisition of an allergy-line from a pharmaceutical company in Bilbao, Spain has established a strong foundation for future growth. With over 70 years of focus on immuno-therapy, the company's Bilbao team collaborates closely with leading research institutes, bolstering their potential for developing groundbreaking new treatments.
Moreover, their subsidiary company, DR. BECKMANN Pharma, offers medical products designed to alleviate various allergy symptoms. Their product portfolio includes nasal showers, ointments for sensitive skin, high-quality allergen encasings, and peak-flow meters.
In conclusion, ROXALL Group's commitment to cutting-edge allergen immunotherapy and the expansion of its product range through DR. BECKMANN Pharma positions it as a key player in the pharmaceutical industry. With a strong international presence and a focus on innovation, the company is poised for significant growth and continued success.
